Emrosi approved by FDA on November 4 for the treatment of inflammatory lesions of rosacea in adults Cosibelimab PDUFA goal date of December 28 for potential approval to treat metastatic or locally adv ...
(Alliance News) - The following stocks are the leading risers and fallers on AIM on Friday.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback